Effects of Memantine to improve cognitive disorders caused by ECT in patients with major depressive disorder

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT201506203930N38

Enrollment

Registered

2016-07-01

Start date

2016-05-28

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Major depressive disorder. Depressive episode

Interventions

Intervention 1: Memantin (5mg/day) started and increase to 20mg/day. Intervention 2: Tablet.

Treatment - Drugs

Placebo

Memantin (5mg/day) started and increase to 20mg/day

Tablet

Eligibility

Sex/Gender

All

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Aged between 18 to 65, both gender, major depressive dsorder using DSM-IV criteria Exclusion criteria: serious medical condition, hypothyroidism, bipolar mood disorder, pregnancy

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Depression Score. Timepoint: Baseline, the last session of ECT and 2 weeks after the last session of ECT. Method of measurement: Minimal status Examination.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAli Sahraian

Shiraz University of Medical Sciences

sahraian@sums.ac.ir+98 71 3627 3070

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026